Clin2
NCT06068439Possibly a fitNot yet recruiting

Low-dose aspirin for kidney protection in early diabetic kidney disease

Diabetic Nephropathy Type 2

Treatments studied

Part of Hormones & metabolism, Kidney & urinary clinical trials.

This study tests whether a low dose of aspirin can protect the kidneys in people with early diabetic kidney disease. It aims to see if aspirin slows down kidney damage without causing serious side effects.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
355 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You must have kidney damage due to diabetes (diabetic nephropathy) and be in stage 3 or earlier (eGFR above 30).
  • You cannot have had a major bleeding event or a stomach ulcer in the past.
  • You must not be currently taking aspirin, ibuprofen, or other blood thinners.
  • Your blood sugar and blood pressure should be well-controlled (A1c below 8% and blood pressure below 140/85).
  • You must not have serious heart rhythm problems, liver disease, or active cancer (except certain skin cancers).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04381143Recruiting· Phase 4
Aspirin to prevent problems in people on dialysis

This trial studies whether taking aspirin can reduce heart and clot-related complications in adults receiving long-term dialysis. It may help by improving blood clotting behavior, but it also requires that aspirin is safe for you.

Fuzhou, Fujian
NCT05702463Recruiting· Phase 1
Daily aspirin in adults with type 2 diabetes

This early-stage study tests how a daily aspirin tablet behaves in the body and how it affects blood/clotting markers in people with type 2 diabetes. It may help researchers understand whether this form of aspirin could be useful, especially if you’re not currently taking aspirin.

Montreal, Quebec
NCT05633810Recruiting· Phase 3
Testing colchicine plus coated aspirin to prevent heart events

This Phase 3 study tests whether colchicine and a special type of aspirin can lower the risk of future heart attacks, strokes, or other major heart problems in people with type 2 diabetes who have not had a prior heart event. It aims to reduce cardiovascular risk using medicines that may calm inflammation and protect blood vessels.

Bentley, Western Australia
NCT07434791Not yet recruiting
Reducing kidney and heart risk in diabetes with targeted therapy

This study tests a personalized medication approach to lower kidney and heart risks in people with type 2 diabetes and early-to-moderate kidney disease. It may help you if you have a high chance of heart problems and can start new medications.

NCT07587918Not yet recruiting
Diet and kidney health in type 2 diabetes

This study looks at how different foods affect kidney health in people with type 2 diabetes and early kidney disease. Researchers will compare dietary patterns across different ethnic groups to understand what helps protect kidneys.

Rotterdam
NCT07496177Recruiting· Phase 2
HTD1801 for kidney function in diabetes and kidney disease

This trial tests whether a new drug, HTD1801, can protect or improve kidney function in people with type 2 diabetes and chronic kidney disease. It may help slow kidney damage and reduce protein in urine.

Weifang, Shandong

Hear when a new Diabetic Nephropathy Type 2 trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.